GIFLF - Grifols, S.A.
| Previous Close | 11.65 |
| Open | 11.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 11.65 - 11.65 |
| 52 Week Range | 7.90 - 21.00 |
| Volume | |
| Avg. Volume | 153 |
| Market Cap | 7.501B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | 35.30 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | N/A |
- Motley Fool
Why Shares of Grifols Were Up Tuesday
Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released first-quarter earnings on Tuesday morning. The company's products range from diagnostics to detect infectious agents in blood or plasma donations, to the production of antigens used in immunoassay regents, to albumin, used to restore circulatory volume and protein loss in certain conditions.
- Zacks
Are Investors Undervaluing Grifols (GRFS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Grifols (GRFS) Upgraded to Strong Buy: Here's Why
Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- Reuters
UPDATE 2-Grifols' shares tank 10% as 2023 outlook disappoints
Spanish pharmaceutical company Grifols' shares fell around 10% in afternoon trading after its 2023 outlook disappointed analysts, who were looking for a better recovery in margins. Grifols' shares were 9.6% down at 15:44 GMT and were the worst performers on the blue-chip Spanish Ibex index, which was up 0.97%. Grifols reported on Tuesday that net profit rose 10% to 208 million euros ($220.19 million).
- Zacks
Is Grifols (GRFS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Reuters
Grifols to lay off 8.5% of workforce under $427 million savings plan
Spanish pharmaceutical firm Grifols plans to lay off around 2,300 employees, or 8.5% of its global workforce, amid a strategy overhaul aimed at reaching annual savings of around 400 million euros ($427 million), it said on Wednesday. The company, which uses blood plasma to make medicines, said in a statement it would cut 2,000 jobs at its plasma business in the United States this year, as it seeks to have a "more efficient" platform to obtain plasma and to lower costs. Grifols expects savings of 100 million euros to be reflected in its 2023 balance sheet, while the remaining 300 million would be added in 2024.
- Reuters
Grifols to lay off 8.5% of workforce under $427 mln savings plan
Spanish pharmaceutical firm Grifols plans to lay off around 2,300 employees, or 8.5% of its global workforce, amid a strategy overhaul aimed at reaching annual savings of around 400 million euros ($427 million), it said on Wednesday. The company, which uses blood plasma to make medicines, said in a statement it would cut 2,000 jobs at its plasma business in the United States this year, as it seeks to have a "more efficient" platform to obtain plasma and to lower costs. Grifols expects savings of 100 million euros to be reflected in its 2023 balance sheet, while the remaining 300 million would be added in 2024.
- Zacks
Is Grifols (GRFS) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Reuters
Grifols considers selling 2 bln euros worth of assets to cut debt, Cinco Dias says
Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing unidentified financial sources. The company may sell its Chinese business and its diagnoses unit, Cinco Dias reported. A spokesperson for the company declined to comment though in November Grifols said it was committed to reducing its 9.4 billion net debt.
- Reuters
Spanish pharmaceuticals firm Grifols reports 30% drop in nine-month profit
Spanish pharmaceutical company Grifols reported a 30% drop in nine-month net profit on Tuesday, due in part to acquisition costs. Grifols said it was still on track to meet its full-year financial targets, but its shares fell 4.2% in morning trade. The company, which uses blood plasma to make medicines, saw its business severely hit by the pandemic as blood collection was halted in many countries.
- Reuters
Grifols says U.S. blood donors' lawsuit won't have material impact, shares down
Spanish pharma group Grifols said on Friday a lawsuit filed in the United States by blood donors who claim the company violated their privacy would have no material impact, after a report in newspaper El Economista sent the shares sharply lower. The company said about 54,000 donors in Illinois had filed a lawsuit claiming Grifols breached data protection regulations, confirming the newspaper report. Grifols shares were down 5.3% on Friday morning, briefly the worst performer on the blue-chip Ibex-35 index, which was down 2.1%.
- Reuters
Grifols appoints executive chairman as seeks to speed recovery
Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year. Steven F. Mayer, an independent board member since 2011 and a former senior managing director of Cerberus Global Private Equity, will become executive chairman, effective immediately. The company's outgoing non-executive chairman, Victor Grifols Roura, who was chief executive from 1987 to 2016, has been named honorary chairman.
- Reuters
Grifols not currently planning capital increase - source
BARCELONA (Reuters) -Spanish pharmaceuticals company Grifols has no current plans for a capital increase, a company executive told investors on Thursday in response to a news report, a source with knowledge of the matter said. The source said Grifols vice president Nuria Pascual read a statement on behalf of Grifols' chairman, Victor Grifols Roura at an investor day on Thursday, which said: "Regarding the unexpected news published yesterday in Spanish media and replicated by the financial press we want to inform that, for the time being, the board is not analysing any increase in share capital."
- Reuters
Grifols' shares fall 6% on media report of possible capital increase
Shares of Spanish pharmaceuticals company Grifols were down 6% on Wednesday morning after news website El Confidencial reported the company was considering a 2 billion euro ($2.10 billion) capital increase to reduce its debt. Quoting unidentified market sources, the news outlet reported that Grifols, which specialises in blood plasma-based drugs, was negotiating with several funds over a capital increase equivalent to almost 20% of the company valuation. A spokesperson at Grifols said the company would not comment on market rumours.
